A breath Full of Life – The Importance of Movement and Physiotherapy in the Treatment of Children with Cystic Fibrosis
DOI:
https://doi.org/10.12775/QS.2025.41.60113Keywords
Cystic fibrosis, genetic disease, CFTR gene, respiratory physiotherapy, physical activity, respiratory system, breathing exercisesAbstract
Cystic fibrosis is a congenital genetic disease that cannot be acquired or passed on through contact with another person. It occurs in both boys and girls because its cause is a genetic mutation present from birth. The disease develops when a child inherits two defective genes - one from the mother and the other from the father. Parents, although not suffering from the disease themselves, are carriers of the mutation and can pass it on to their offspring. Chronic inflammation gradually destroys the lung parenchyma, causing changes such as bronchodilation, fibrosis and sometimes emphysema or atelectasis. As the disease progresses, respiratory failure occurs, leading to hypoxia and a significant reduction in physical endurance in patients with cystic fibrosis. Regular physical activity and properly selected physiotherapy are a key component of cystic fibrosis therapy. They support the functioning of the respiratory system, improving patients' quality of life. Systematic exercise and specialized drainage techniques facilitate the removal of secretions from the lungs, strengthen respiratory muscles and increase overall fitness.
References
[1] Trouvé P, Saint Pierre A, Férec C. Cystic Fibrosis: A Journey through Time and Hope. Int J Mol Sci 2024;25. https://doi.org/10.3390/ijms25179599.
[2] Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis 2022;21:456–62. https://doi.org/10.1016/j.jcf.2022.01.009.
[3] Wang G. Genome Editing for Cystic Fibrosis. Cells 2023;12. https://doi.org/10.3390/cells12121555.
[4] Einarsson GG, Sherrard LJ, Hatch JE, Zorn B, Johnston E, McGettigan C, et al. Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment. Journal of Cystic Fibrosis 2024;23:252–61. https://doi.org/10.1016/j.jcf.2023.11.010.
[5] Mésinèle J, Ruffin M, Guillot L, Boëlle PY, Corvol H. Airway infections as a risk factor for Pseudomonas aeruginosa acquisition and chronic colonisation in children with cystic fibrosis. Journal of Cystic Fibrosis 2023;22:901–8. https://doi.org/10.1016/j.jcf.2023.06.007.
[6] Mingora CM, Flume PA. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest 2021;160:1232–40. https://doi.org/10.1016/j.chest.2021.06.017.
[7] Bush A, Floto RA. Pathophysiology, causes and genetics of paediatric and adult bronchiectasis. Respirology 2019;24:1053–62. https://doi.org/10.1111/resp.13509.
[8] Kimple AJ, Senior BA, Naureckas ET, Gudis DA, Meyer T, Hempstead SE, et al. Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol 2022;12:1089–103. https://doi.org/10.1002/alr.22974.
[9] Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020;8:65–124. https://doi.org/10.1016/S2213-2600(19)30337-6.
[10] Burgel PR, Southern KW, Addy C, Battezzati A, Berry C, Bouchara JP, et al. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. Journal of Cystic Fibrosis 2024;23:187–202. https://doi.org/10.1016/j.jcf.2024.01.005.
[11] Main E, Rand S. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database of Systematic Reviews 2023;2023. https://doi.org/10.1002/14651858.CD002011.pub3.
[12] Filipow N, Stanojevic S, Raywood E, Shannon H, Tanriver G, Kapoor K, et al. Real-world effectiveness of airway clearance techniques in children with cystic fibrosis. European Respiratory Journal 2023;62. https://doi.org/10.1183/13993003.00522-2023.
[13] Wilson LM, Morrison L, Robinson KA. Airway clearance techniques for cystic fibrosis: An overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews 2019;2019. https://doi.org/10.1002/14651858.CD011231.pub2.
[14] Morrison L, Milroy S. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2020;2020. https://doi.org/10.1002/14651858.CD006842.pub5.
[15] Declercq D, Van Meerhaeghe S, Marchand S, Van Braeckel E, van Daele S, De Baets F, et al. The nutritional status in CF: Being certain about the uncertainties. Clin Nutr ESPEN 2019;29:15–21. https://doi.org/10.1016/j.clnesp.2018.10.009.
[16] Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews 2021;2021. https://doi.org/10.1002/14651858.CD001127.pub5.
[17] Terlizzi V, Castellani C, Taccetti G, Ferrari B. Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index. Ital J Pediatr 2022;48. https://doi.org/10.1186/s13052-022-01331-5.
[18] Martin C, Burnet E, Ronayette-Preira A, de Carli P, Martin J, Delmas L, et al. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Respir Med Res 2021;80. https://doi.org/10.1016/j.resmer.2021.100829.
[19] Manika K, Diamantea F, Tsakona A, Kakolyris A, Sopiadou A, Kotoulas SC, et al. Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation. Journal of Cystic Fibrosis 2024;23:29–31. https://doi.org/10.1016/j.jcf.2023.05.001.
[20] Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Dalfsen JM, Singh SBP, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. Journal of Clinical Investigation 2023;133. https://doi.org/10.1172/JCI167957.
[21] Southern KW, Solis-Moya A, Kurz D, Smith S. Macrolide antibiotics (including azithromycin) for cystic fibrosis. Cochrane Database of Systematic Reviews 2024;2024. https://doi.org/10.1002/14651858.CD002203.pub5.
[22] Kutney KA, Sandouk Z, Desimone M, Moheet A. Obesity in cystic fibrosis. J Clin Transl Endocrinol 2021;26. https://doi.org/10.1016/j.jcte.2021.100276.
[23] Gramegna A, Majo F, Alicandro G, Leonardi G, Cristiani L, Amati F, et al. Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis. Respir Res 2023;24. https://doi.org/10.1186/s12931-023-02451-0.
[24] Frost F, Nazareth D, Fauchier L, Wat D, Shelley J, Austin P, et al. Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study. European Respiratory Journal 2023;62. https://doi.org/10.1183/13993003.00174-2023.
[25] Radtke T, Smith S, Nevitt SJ, Hebestreit H, Kriemler S. Physical activity and exercise training in cystic fibrosis. Cochrane Database of Systematic Reviews 2022;2022. https://doi.org/10.1002/14651858.CD002768.pub5.
[26] Gruet M, Saynor ZL, Urquhart DS, Radtke T. Rethinking physical exercise training in the modern era of cystic fibrosis: A step towards optimising short-term efficacy and long-term engagement: Rethinking physical exercise training in CF. Journal of Cystic Fibrosis 2022;21:e83–98. https://doi.org/10.1016/j.jcf.2021.08.004.
[27] Grzeczyńska M, Grzelewska A, Grzelewski T, Majak P, Stelmach I. The impact of cystic fibrosis course on the physical activity of children with cystic fibrosis. Nursing Problems / Problemy Pielęgniarstwa. 2011;19(1):39-46.
[28] Ratjen F, Döring G. Cystic fibrosis. Lancet, vol. 361, Elsevier B.V.; 2003, p. 681–9. https://doi.org/10.1016/S0140-6736(03)12567-6.
[29] Heinz KD, Walsh A, Southern KW, Johnstone Z, Regan KH. Exercise versus airway clearance techniques for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2022;2022. https://doi.org/10.1002/14651858.CD013285.pub2.
[30] Ward N, Morrow S, Stiller K, Holland AE. Exercise as a substitute for traditional airway clearance in cystic fibrosis: A systematic review. Thorax 2021;76:763–71. https://doi.org/10.1136/thoraxjnl-2020-215836.
[31] Heinz KD, Walsh A, Southern KW, Johnstone Z, Regan KH. Exercise versus airway clearance techniques for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2022;2022. https://doi.org/10.1002/14651858.CD013285.pub2.
[32] Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, et al. Quality of life is associated with physical activity and fitness in cystic fibrosis. BMC Pulm Med 2014;14. https://doi.org/10.1186/1471-2466-14-26.
[33] Dwyer TJ, Daviskas E, Zainuldin R, Verschuer J, Eberl S, Bye PTP, et al. Effects of exercise and airway clearance (positive expiratory pressure) on mucus clearance in cystic fibrosis: A randomised crossover trial. European Respiratory Journal 2019;53. https://doi.org/10.1183/13993003.01793-2018.
[34] Rand S, Prasad SA. Exercise as part of a cystic fibrosis therapeutic routine. Expert Rev Respir Med 2012;6:341–52. https://doi.org/10.1586/ers.12.19.
[35] Williams, Craig A et al. Expert guidelines on exercise and physical activity for people with cystic fibrosis. British journal of hospital medicine (London, England : 2005) vol. 29,3 (2023): 1-3. doi:10.12968/hmed.2023.0050
[36] Kinaupenne M, Van Biervliet S, Van Hoorenbeeck K, Schaballie H, Vandekerckhove K, Demeyer H, et al. Lower physical activity levels in youth with Cystic Fibrosis compared to healthy controls: A multicentre comparative study. Respir Med 2024;232. https://doi.org/10.1016/j.rmed.2024.107749.
[37] Shelley J, Fairclough SJ, Knowles ZR, Southern KW, McCormack P, Dawson EA, et al. A formative study exploring perceptions of physical activity and physical activity monitoring among children and young people with cystic fibrosis and health care professionals. BMC Pediatr 2018;18. https://doi.org/10.1186/s12887-018-1301-x.
[38] Pinto ACPN, Piva SR, Rocha A, Gomes-Neto M, Atallah ÁN, Saconato H, et al. Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2023;2023. https://doi.org/10.1002/14651858.CD014605.pub2.
[39] Azab AR, Elnaggar RK, Aloraini GS, Aldhafian OR, Alshahrani NN, Kamel FAH, et al. Adolescents with hemophilic knee arthropathy can improve their gait characteristics, functional ability, and physical activity level through kinect-based virtual reality: A randomized clinical trial. Heliyon 2024;10. https://doi.org/10.1016/j.heliyon.2024.e28113.
[40] Chen HL, Lin SY, Yeh CF, Chen RY, Tang HH, Ruan SJ, et al. Development and Feasibility of a Kinect-Based Constraint-Induced Therapy Program in the Home Setting for Children With Unilateral Cerebral Palsy. Front Bioeng Biotechnol 2021;9. https://doi.org/10.3389/fbioe.2021.755506.
[41] Basha MA, Aboelnour NH, Aly SM, Kamel FAH. Impact of Kinect-based virtual reality training on physical fitness and quality of life in severely burned children: A monocentric randomized controlled trial. Ann Phys Rehabil Med 2022;65. https://doi.org/10.1016/j.rehab.2020.101471.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Katarzyna Oświeczyńska, Aleksandra Sowa, Kacper Trząsalski, Patrycja Jędrzejewska-Rzezak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 120
Number of citations: 0
